Advancements in Neuroendocrine Tumor Imaging Highlight Access Disparities

Recent research from the Harvey L. Neiman Health Policy Institute has unveiled significant disparities in patient access to diagnostic technologies for neuroendocrine tumors. The introduction of PET-based radiotracers, specifically Gallium-68 DOTATATE/DOTATOC, between 2017 and 2020, demonstrated a notable shift in travel distances for patients depending on their geographic location.

The study, published in the Journal of the American College of Radiology, analyzed 3,365 claims concerning neuroendocrine tumor imaging. It was observed that patients in small-town and rural areas needed to travel an additional 134.9 miles on average to access PET-based imaging compared to their metropolitan counterparts, who traveled an additional 26.7 miles.

Gallium-68 DOTATATE/DOTATOC, known for its clinical superiority over the older SPECT-based Indium-111 pentetreotide, has limitations due to its short 68-minute half-life, necessitating local production. This requirement has created significant access barriers for rural patients, as noted by Cindy Yuan, MD, from the Indiana University School of Medicine, the study's lead author.

The study underscores the importance of theranostics in cancer care, a method combining diagnostic imaging with treatment. While Gallium-68 facilitated precise tumor mapping, it also paved the way for therapeutic advancements, such as the introduction of Lutetium-177 DOTATATE in 2018.

To address the accessibility concerns introduced by the short half-life of Gallium-68, a new radiotracer, Copper-64 DOTATATE, was introduced in 2021. With a longer half-life of 12.7 hours, Copper-64 has helped bridge the access gap, as highlighted by Eric Christensen, PhD, Research Director at the Neiman Institute. By 2023, the usage patterns had evolved, with Gallium-68 and Copper-64 sharing the majority of market use and markedly reducing reliance on Indium-111, which represents only 2% of current use.

This shift toward Copper-64 DOTATATE is seen as a move towards more equitable access, particularly for patients in rural areas. Dr. Elizabeth Rula, PhD, co-author of the study, emphasized that these disparities in diagnostic access are reflective of similar challenges in therapeutic access.

In conclusion, while Gallium-68 maintains clinical advantages, logistical and economic factors play a crucial role in its application. The strategic use of Copper-64 in smaller markets aims to enhance accessibility, addressing both clinical efficacy and patient convenience.